or Try an Advanced Search...

    ETF Components for CNCR - Loncar Cancer Immunotherapy ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    GLUE C 2.27 2.03
    EXEL B 0.06 1.90
    RVMD B 1.05 1.84
    ACLX C 0.41 1.73
    BMY B 0.00 1.72
    ELVN C -0.16 1.68
    XNCR B 0.51 1.66
    MRSN C 0.00 1.62
    BPMC C 1.02 1.58
    KPTI D -0.62 1.57
    REPL C -0.80 1.56
    GNLX D 0.51 1.56
    MGNX D -1.22 1.55
    HCM C -0.78 1.54
    SWTX C -2.07 1.47
    CRBU D -0.26 1.47
    JANX C -3.11 1.46
    ERAS C -3.60 1.46
    DAWN D -1.62 1.44
    IMCR C -0.35 1.42
    RXRX D -5.05 1.39
    SDGR C -0.57 1.39
    ARVN F 2.78 1.39
    AURA C 0.00 1.38
    LYEL F -6.72 1.35
    SNDX F -4.33 1.34
    MRUS F 2.10 1.33
    KYMR D -0.83 1.32
    RPTX F 1.41 1.32
    GERN C 0.63 1.31
    IOVA F 2.09 1.30
    RCUS F -1.85 1.29
    NRIX C 0.62 1.29
    FHTX C 3.56 1.26
    NUVB C 2.31 1.26
    BNTX D 1.48 1.25
    ZNTL D -1.92 1.25
    MRK F 0.88 1.24
    BCYC F -1.28 1.24
    YMAB F -0.14 1.24
    BMEA F -1.83 1.22
    PGEN F 4.48 1.20
    CGEM F -2.62 1.20
    ALLO F -0.98 1.18
    NUVL D 1.73 1.18
    VOR D -0.62 1.17
    GMAB F 0.34 1.17
    TYRA F 0.19 1.16
    KURA F -38.09 1.16
    ACRV F -0.31 1.15
    AUTL F -1.61 1.13
    STRO F -3.37 1.12
    LEGN D -0.97 1.10
    IDYA F 1.76 1.07
    TSVT F -0.96 1.06
    REGN F 0.28 1.00
    ITOS F 0.48 0.98
    IPHA F 0.00 0.98
    SMMT D -1.07 0.97
    ACET F -3.85 0.97
    IMRX F 0.00 0.95
    IMTX F 1.38 0.93
    RLAY F -0.88 0.91
    IGMS F 0.00 0.88
    RAPT F -2.80 0.88
    FATE F -5.18 0.87
    PRLD F -2.26 0.55

    Represented by ETF Holdings

    Keywords: Cancer Biopharmaceutical Medicine Biotechnology Clinical Medicine Life Sciences Immunology Solid Tumors Antibodies Biology Immune System Cancer Treatment Drug Discovery Treatment Of Cancer Tyrosine Kinase Receptors Monoclonal Antibodies Oncology Disease Tumor Acute Myeloid Leukemia
    Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services Long-Term Care Facilities

    Recent News for Loncar Cancer Immunotherapy ETF & its Holdings

    Date Stock Title
    Nov 21 KURA Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
    Nov 21 SDGR Schrödinger: Positive Signs Despite The Share Price Decline
    Nov 21 KURA Kura Oncology partners Kyowa Kirin to advance AML treatment
    Nov 21 AUTL AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
    Nov 20 KURA Kura stock slides 17% on Kyowa Kirin deal for ziftomenib
    Nov 20 KURA Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
    Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
    Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
    Nov 20 KPTI Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
    Nov 20 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
    Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Nov 20 MRK Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
    Nov 20 MRK Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
    Nov 20 SWTX SpringWorks started at outperform by Evercore ahead of FDA decision
    Nov 20 RXRX Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
    Nov 20 PGEN Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%
    Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
    Nov 20 SDGR Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
    Nov 20 SMMT Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why
    Nov 20 RXRX Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
    ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.
    Exchange Traded Fund ETF Exchange Traded Funds Biotechnology SPDR Cancer Betashares Immune System Immunotherapy Cancer Immunotherapy Biotechnology Sectors Lonca
    Back to the Main CNCR Page...